NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)

NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $2.59M NIH Research Grant to Lead Researcher Behind Its Diabetes Gene Therapy

Genprex (NASDAQ: GNPX), today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the company’s potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (“NIH”) National Institute of Diabetes and Digestive and Kidney Diseases. According to the update, the grant will assist Dr. Gittes’ development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes. “We are excited to receive this funding to support our research in diabetic primates as we move toward human clinical trials,” Dr. George Gittes, Co-Scientific Director and Professor of Surgery at the University of Pittsburgh Medical Center (“UPMC”) Children’s Hospital of Pittsburgh and the lead researcher behind the diabetes gene therapy. “We saw encouraging data in our preclinical mice studies, where the gene therapy reprogrammed pancreatic cells to restore normal blood glucose levels in diabetic mice for approximately four months, which could translate to decades in humans. More recently, preliminary results in non-human primates (monkeys) has also been very promising.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer